Exagen Inc (XGN) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $8.23 (+4.57%), Market cap $0.09B, 52-week low–high $2.65 ~ $11.96.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by
Financial statements, price targets, institutional (13F) holdings and related news for Exagen Inc are updated in real time on BlackAll Trade.
Exagen Inc trades at $8.23 (+4.57%). Real-time quotes and charts are available on BlackAll Trade.
Exagen Inc has a market cap of about $0.09B.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnos